Hemophilia of Georgia, Inc., has awarded gifts to Emory University School of Medicine totaling $2.25 million to create two endowed faculty positions focused on hemophilia or related inherited bleeding disorders. The Hemophilia of Georgia, Inc., Research Chair in Hemostasis and the Hemophilia of Georgia, Inc., Professorship in Hemostasis will be located within the Emory Department of Pediatrics and Children's Healthcare of Atlanta Hemophilia Program of the Aflac Cancer Center and Blood Disorders Service. John S. "Pete" Lollar, MD, is the first recipient of the Hemophilia of Georgia, Inc. Research Chair in Hemostasis.
The Emory/Children's Hemophilia Program is a national leader in research and treatment programs that are helping improve the lives of the 17,000 hemophiliacs living in the U.S. Individuals with hemophilia are missing the normal gene that makes factor VIII or IX, a critical part of the blood clotting machinery.
The Emory/Children's comprehensive adult and pediatric hemophilia program currently treats 500 patients, including 290 children. The program is located at two sites; at the Emory campus and at the Children's Healthcare of Atlanta at Scottish Rite facility. The Medical Director is Thomas Abshire, MD, Emory professor of pediatrics at the Aflac Cancer Center and Blood Disorders Service of Children's.
Dr. Lollar has been an Emory faculty member in the Department of Medicine and the Winship Cancer Institute since 1990. He has been internationally recognized for more than 20 years of groundbreaking research and contributions to the structure and function of factor VIII. Among his many achievements is the construction of a new recombinant porcine factor VIII molecule for use in patients who develop inhibitors to factor VIII. He is co-founder of Octagen Corporation, a pharmaceutical company designed to further the development of this new product, which currently is in Phase II clinical trials. A graduate of the St. Louis University Medical School in 1977, he was chief medical resident at the University of Iowa, then a research associate in hematology at the Mayo Clinic.
"We are immensely grateful to Hemophilia of Georgia for supporting our efforts to address bleeding disorders through a comprehensive program of treatment and research," said Thomas J. Lawley, MD, dean of Emory University School of Medicine.
Hemophilia of Georgia (http://www.hog.org/index.htm) is a non-profit agency established in 1973 to help serve the needs of the bleeding disorders community in Georgia. The agency provides pharmacy, nursing and social support services, educational resources, activities and camping programs. It also provides research grants to help scientists working to discover improved treatments for these disorders.
William G. Woods, MD, the Daniel P. Amos Children's Chair and director of the Aflac Cancer Center and Blood Disorders Service of Children's adds, "Hemophilia of Georgia is one of the foremost national institutions which supports both optimal patient care and research for hemophilia. This endowment will directly help patients with this devastating disease."
Mr. Robert Carton, Chairman of the Board of Hemophilia of Georgia, notes "the Board, staff and volunteers of Hemophilia of Georgia are extremely proud of this funding for Emory to help ensure their ongoing partnership and to provide world class care for those affected by a bleeding disorder, as well as state-of-the-art research. For more than 20 years, Hemophilia of Georgia, Emory and Children's have worked to provide patient care to the Georgia bleeding disorder community in an atmosphere of mutual respect, admiration and cooperation, and the endowment of this research chair opens a new chapter in our relationship."